Search
Guardant Health Inc
GHAdd to Watchlist
153.740USD
+4.520+3.03%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
20.22BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.03%
5 Days
+19.34%
1 Month
+18.54%
6 Months
+51.63%
Year to Date
+50.52%
1 Year
+202.28%
Key Figures
150.000Open
153.950High
2.73MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.08%Turnover Ratio
149.220Prev. Close
148.460Low
309.05MTurnover
LossP/E Static
-111.66P/B
0.00%Div Yield TTM
-26.58%ROA
133.70552wk High
0.48Volume Ratio
-436.37MNet Profit
131.51MShares
-3.4058EPS TTM
1.60Beta
-4584.47%ROE
38.03052wk Low
3.68%Amplitude
65.22%Gross Margin
20.22BMarket Cap
5.02Reward/Risk
3.00%Risk Rate
TradingKey Stock Score of Guardant Health Inc
Currency: USD Updated: 2026-06-29Key Insights
Guardant Health Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 146.18.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Guardant Health Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Guardant Health Inc Highlights
StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 74.13% year-on-year.
Undervalued
The company’s latest PE is -45.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 134.76M shares, decreasing 3.46% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 352.52K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.36.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
146.184
Target Price
-2.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Guardant Health Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Guardant Health Inc Info
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Ticker SymbolGH
CompanyGuardant Health Inc
CEOTalasaz (Amirali)
Websitehttps://guardanthealth.com/
Related Instruments
-1.97%
-1.34%
-1.50%
+0.31%
-1.73%
-0.74%
-0.71%
-0.09%
+0.08%
-1.83%
-1.45%
-1.76%
-1.57%
+0.44%
+1.33%
-0.49%
-2.82%
+3.97%
-2.31%
-1.49%Popular Instruments
FAQs
What is the current price of Guardant Health Inc (GH)?
The current price of Guardant Health Inc (GH) is 153.74.
What is the symbol of Guardant Health Inc?
The ticker symbol of Guardant Health Inc is GH.
What is the 52-week high of Guardant Health Inc?
The 52-week high of Guardant Health Inc is 133.71.
What is the 52-week low of Guardant Health Inc?
The 52-week low of Guardant Health Inc is 38.03.
What is the market capitalization of Guardant Health Inc?
The market capitalization of Guardant Health Inc is 20.22B.
Is Guardant Health Inc (GH) currently rated as Buy, Hold, or Sell?
According to analysts, Guardant Health Inc (GH) has an overall rating of Buy, with a price target of 146.18.
What is the Earnings Per Share (EPS TTM) of Guardant Health Inc (GH)?
The Earnings Per Share (EPS TTM) of Guardant Health Inc (GH) is -3.32.
